

REGISTERED COMPANY NUMBER: 08820009 (England and Wales)
REGISTERED CHARITY NUMBER: 1156666

REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR
ENDED 31 DECEMBER 2018
FOR
PHELIX RESEARCH AND DEVELOPMENT

Watts Gregory LLP
Chartered Accountants
Elfed House
Oak Tree Court
Cardiff Gate Business Park
CARDIFF
County of Cardiff
CF23 8RS

PHELIX RESEARCH AND DEVELOPMENT

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2018**

	Page
Report of the Trustees	1 to 3
Independent Examiner's Report	4
Statement of Financial Activities	5
Balance Sheet	6
Notes to the Financial Statements	7 to 9

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2018. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The charity's objects as stated in its Articles of Association are:

"To protect and promote the health of the public in particular by research into the nature, cases, diagnosis, prevention, treatment and cure of chronic infection diseases, including the development of findings of research into practical applications for the prevention treatment and cure of chronic infection diseases and in furtherance of that primary objective, to support information and raise public understanding of such matters, and to support the research on bacteriophages for bacterial infections in a chronic phase and to develop therapeutic programs based on bacteriophages."

Phelix Research & Development (Phelix R&D) is a medical research charity. The charity works hand in hand with Phelix France, registered in France as an 'Association d'Intérêt Général'.

Its team is a strong co-partnership of healthcare professionals (practitioners, immunologists and university researchers, amongst them Leicester University) and volunteers, working together to reach the charity's key objectives.

The overall aim is to develop phage-based diagnostic and treatment of Lyme disease. To-date, we have developed a novel phage-based diagnostic method targeting Lyme *Borrelia* strains. This novel diagnostic method showed higher sensitivity compared to the current diagnostic methods. With further development, our phage-based method could have the power to distinguish between active and non-active Lyme infection and offer a promise of early Lyme diagnostics.

In addition to our pioneer work in Lyme diagnostics, we have also developed our pipelines of methodologies in isolation and identification of phages that specifically infect Lyme *Borrelia* strains, and we are currently actively screening for phages. Once we identify phages, we will test the efficacy of these phages in killing *Borrelia* strain, and develop them towards therapeutics.

Clinical Trial of the Phage-Based test for Lyme Disease

Presentation of the study

2018: clinical trials on 120 patients were conducted, involving 3 groups:

- (i) early stages (less than 6 months after bite, with or without EM and clinical symptoms);
- (ii) late stages (PLTD existing more than 6 months after the bite); and
- (iii) healthy volunteers.

At the end of 2018, recruitment was achieved and all subjects were clinically documented. For each subject antibody based tests ELISA and WB results were obtained.

We also studied lytic-phages' enzymes and compounds activity on *Borrelia* cultures. Results of various compositions were presented.

Results and conclusions

Borrelia phage-based qPCR test is a direct proof of an active infection, very specific and more sensitive than any current ELISA, Western Blot, PCRs. It can be used in controversial late stages of infection, and in early stages when antibodies are not present and LTTs non effective. They will allow clinicians to evaluate treatments' efficacy. Our preliminary work on therapeutic bacteriophages suggests that the phage enzyme-based compounds will be effective boosters of current antibiotic cocktails, in persistent infections by bacteria with varying susceptibilities to drugs, varying forms, forming micro biofilms-like aggregates viable despite aggressive long lasting antibiotic challenges.

PHELIX RESEARCH AND DEVELOPMENT

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2018

Conferences in 2018

Louis Teulieres (Phelix R&D trustee)

- Speaker CHRONIMED Workshop September 7th 2018 Paris
- Speaker 5th to 10th October 2018 ALCE (Lyme and co-infections Patients association Madrid Invited)
- Speaker 1st -3rd of November 2018, International Lyme and Associated Diseases Society 19th Annual Conference, Chicago.

Jinyu Shan (Head of Research, Leicester University)

- Poster presentation, 1st-3rd November 2018, International Lyme and Associated Diseases Society 19th Annual Conference, Chicago, USA
- Keynote speaker, 6th-7th August 2018, Qilu International Forum, Shandong Academy of Agriculture Sciences, Jinan, P.R.China
- Invited speaker, 9th-13th July 2018, EMBO Workshop Viruses of Microbes, July 2018 Wroclaw, Poland
- Poster presentation, 15th - 16th June 2018, International Lyme and associated diseases society (ILADS), 8th European Conference, Warsaw, Poland
- Invited poster presentation, 12th March 2018, STEM for Britain poster presentation in the Parliament, London, UK

Charity personnel and membership

Laurence Jouinot and Philippe Bottero, original member left the Charity but they are still very close to our work and activities.

OBJECTIVES AND ACTIVITIES

Public benefit

The trustees can confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charities Commission. Significant activities that we undertook during the year that demonstrate public benefit are set out above.

FINANCIAL REVIEW

Financial position

During the year, the charity incurred expenditure of £78,400 (2017 : £43,329) this was funded by the trustees and a loan from Phelix France.

François- Xavier Louvet, founding trustee, increased the notional loan facility agreement with 0% interest by £24,250.

Phelix France agreed to lend Phelix R&D, €80,000 under a 4 year contract.

Reserves policy

Whilst the trustees are aware of the need to build reserves for a sustainable future, this is not considered necessary at this time due to the support of the trustees.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is governed by its Memorandum and Articles of Association and constitutes a company limited by guarantee, as defined by the Companies Act 2016.

Recruitment and appointment of new trustees

Trustees are appointed or removed or retire by resolution of the trustees at board meeting or the Annual General Meeting.

Organisational structure

The Board of Trustees administers the company. The Board meets quarterly.

Induction and training of new trustees

Trustees are fully briefed on their legal obligations under charity and company law. Trustees are also urged to make use of the training and advice available on the Charity Commission website.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

PHELIX RESEARCH AND DEVELOPMENT

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2018**

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number
08820009 (England and Wales)


Registered Charity number
1156666

Registered office
37 Langton Street
Chelsea
LONDON
SW10 0JL

Trustees
Mr F A G C Louvet
Dr L C Teulieres

Independent examiner
Watts Gregory LLP
Chartered Accountants
Elfed House
Oak Tree Court
Cardiff Gate Business Park
CARDIFF
County of Cardiff
CF23 8RS

Approved by order of the Board of Trustees on **23/09/2019** and signed on its behalf by:



.....
Mr F A G C Louvet - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
PHELIX RESEARCH AND DEVELOPMENT**

Independent examiner's report to the trustees of Phelix Research and Development ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2018.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached

Julia Mortimer
Watts Gregory LLP
Chartered Accountants
Elfed House
Oak Tree Court
Cardiff Gate Business Park
CARDIFF
County of Cardiff
CF23 8RS

Date: 23 September 2019

PHELIX RESEARCH AND DEVELOPMENT

**STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2018**

	Notes	2018 Unrestricted fund £	2017 Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies		<u>16</u>	<u>100</u>
Total		16	100
 EXPENDITURE ON			
Charitable activities			
Project running costs		<u>78,400</u>	<u>42,329</u>
NET INCOME/(EXPENDITURE)		(78,384)	(42,229)
RECONCILIATION OF FUNDS			
Total funds brought forward		<u>(234,291)</u>	<u>(192,062)</u>
TOTAL FUNDS CARRIED FORWARD		<u>(312,675)</u>	<u>(234,291)</u>

The notes form part of these financial statements

PHELIX RESEARCH AND DEVELOPMENT

**BALANCE SHEET
AT 31 DECEMBER 2018**

	Notes	2018 Unrestricted fund £	2017 Total funds £
FIXED ASSETS			
Intangible assets	6	19,698	17,863
CURRENT ASSETS			
Cash at bank		1,717	1,394
CREDITORS			
Amounts falling due within one year	7	(780)	(16,243)
NET CURRENT ASSETS/(LIABILITIES)		<u>937</u>	<u>(14,849)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		20,635	3,014
CREDITORS			
Amounts falling due after more than one year	8	(333,310)	(237,305)
NET ASSETS/(LIABILITIES)		<u>(312,675)</u>	<u>(234,291)</u>
FUNDS	9		
Unrestricted funds		<u>(312,675)</u>	<u>(234,291)</u>
TOTAL FUNDS		<u>(312,675)</u>	<u>(234,291)</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2018.


The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2018 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved for issue by the Board of Trustees on 23/09/2019 and were signed on its behalf by:


Mr F A G C Louvet -Trustee

The notes form part of these financial statements

1. STATUTORY INFORMATION

Phelix Research and Development is a registered charity and private company limited by guarantee having no share capital. Members have agreed to contribute £10 in the event of a winding up.

The company is incorporated in the United Kingdom and its registered office is 37 Langton Street, Chelsea, London, SW10 0JL.

The nature of the company's operations and principal activities is disclosed within the Report of the Trustees.

The financial statements are presented in Sterling (£), the company's functional currency, and rounded to the nearest pound.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

The charity has the ongoing support of the trustees.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Intangible assets

Intangible assets acquired separately from a business are capitalised at cost.

Subsequent to initial recognition, intangible assets are stated at cost less accumulated amortisation and accumulated impairment. Intangible assets are amortised on a straight line basis over their estimated useful life. The carrying value of intangible assets is reviewed for impairment if events or changes in circumstances indicate the carrying value may not be recoverable.

The useful economic lives of intangible assets are as follows:

Patents - 10 years

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

PHELIX RESEARCH AND DEVELOPMENT

**NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2018**

3. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2018	2017
	£	£
Patents and licences amortisation	2,189	-
Independent examination	<u>780</u>	<u>780</u>

4. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December 2018 or for the period ended 31 December 2017.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2018 or for the period ended 31 December 2017.

5. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

All expenditure in the period to 31 December 2017 was unrestricted.

6. INTANGIBLE FIXED ASSETS

	Patents and licences £
COST	
At 1 January 2018	17,863
Additions	<u>4,024</u>
At 31 December 2018	<u>21,887</u>
AMORTISATION	
Charge for year	<u>2,189</u>
NET BOOK VALUE	
At 31 December 2018	<u>19,698</u>
At 31 December 2017	<u>17,863</u>

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2018	2017
	£	£
Trade creditors	-	14,683
Accruals and deferred income	<u>780</u>	<u>1,560</u>
	<u>780</u>	<u>16,243</u>

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2018	2017
	£	£
Loan from trustee	261,555	237,305
Other loans	<u>71,755</u>	-
	<u>333,310</u>	<u>237,305</u>

NOTES TO THE FINANCIAL STATEMENTS - CONTINUED
FOR THE YEAR ENDED 31 DECEMBER 2018

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR - continued

The loan from trustee has a term of six years and provides funding facilities to the charity to undertake its research work. The loan is interest free and will only be repayable after the charity secures sufficient independent funding.

The additional loan has a term of four years and also provides funding facilities to the charity to carry out its research work. The loan is interest free and will only be repayable if revenue is generated from licensing its patents.

9. MOVEMENT IN FUNDS

	At 1/1/18 £	Net movement in funds £	At 31/12/18 £
Unrestricted funds			
General fund	(234,291)	(78,384)	(312,675)
TOTAL FUNDS	<u>(234,291)</u>	<u>(78,384)</u>	<u>(312,675)</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	16	(78,400)	(78,384)
TOTAL FUNDS	<u>16</u>	<u>(78,400)</u>	<u>(78,384)</u>

Comparatives for movement in funds

	At 1/1/17 £	Net movement in funds £	At 31/12/17 £
Unrestricted Funds			
General fund	(192,062)	(42,229)	(234,291)
TOTAL FUNDS	<u>(192,062)</u>	<u>(42,229)</u>	<u>(234,291)</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	100	(42,329)	(42,229)
TOTAL FUNDS	<u>100</u>	<u>(42,329)</u>	<u>(42,229)</u>

10. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2018 that require disclosure, other than the loan from trustee as disclosed in note 7.